Search

Your search keyword '"Indolfi, P"' showing total 687 results
Start Over Author "Indolfi, P"
687 results on '"Indolfi, P"'

12. Clinical application of CMR in cardiomyopathies: evolving concepts and techniques: A position paper of myocardial and pericardial diseases and cardiac magnetic resonance working groups of Italian society of cardiology

Author

Merlo, Marco, Gagno, Giulia, Baritussio, Anna, Bauce, Barbara, Biagini, Elena, Canepa, Marco, Cipriani, Alberto, Castelletti, Silvia, Dellegrottaglie, Santo, Guaricci, Andrea Igoren, Imazio, Massimo, Limongelli, Giuseppe, Musumeci, Maria Beatrice, Parisi, Vanda, Pica, Silvia, Pontone, Gianluca, Todiere, Giancarlo, Torlasco, Camilla, Basso, Cristina, Sinagra, Gianfranco, Filardi, Pasquale Perrone, Indolfi, Ciro, Autore, Camillo, and Barison, Andrea

Published
2023
Full Text
View/download PDF

15. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection

Author

Rosenthal, Philip, Schwarz, Kathleen B, Gonzalez‐Peralta, Regino P, Lin, Chuan‐Hao, Kelly, Deidre A, Nightingale, Scott, Balistreri, William F, Bansal, Sanjay, Jonas, Maureen M, Massetto, Benedetta, Brainard, Diana M, Hsueh, Chia‐Hsiang, Shao, Jiang, Parhy, Bandita, Davison, Suzanne, Feiterna‐Sperling, Cornelia, Gillis, Lynette A, Indolfi, Giuseppe, Sokal, Etienne M, Murray, Karen F, and Wirth, Stefan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hepatitis - C, Hepatitis, Liver Disease, Clinical Trials and Supportive Activities, Infectious Diseases, Chronic Liver Disease and Cirrhosis, Clinical Research, Emerging Infectious Diseases, Pediatric, Digestive Diseases, Management of diseases and conditions, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 7.1 Individual care needs, Infection, Good Health and Well Being, Antiviral Agents, Child, Child, Preschool, Drug Combinations, Female, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Male, Ribavirin, Sofosbuvir, Sustained Virologic Response, Treatment Outcome, Medical Biochemistry and Metabolomics, Immunology, Gastroenterology & Hepatology, Clinical sciences
Abstract

Currently, the only approved hepatitis C virus (HCV) treatment for children aged

Published
2020

16. Paediatric-onset autoimmune liver disease: Insights from a monocentric experience.

Author

Curci, Franco, Rubino, Chiara, Stinco, Mariangela, Carrera, Simona, Trapani, Sandra, Bartolini, Elisa, and Indolfi, Giuseppe

Abstract

Autoimmune liver disease (AILD) encompasses autoimmune hepatitis (AIH), autoimmune sclerosing cholangitis (ASC) and primary sclerosing cholangitis (PSC). A unified disease process evolving over time through these entities has been recently suggested. From this perspective, this study aimed to compare the characteristics of childhood-onset AILD at baseline and after a medium-to-long term follow-up period. Paediatric-onset cases of AILD diagnosed between 1992 and 2023 at a tertiary-care centre were reviewed. Patients transitioned to adult-care by the time of data collection were asked for clinical updates. Fifty-five patients were included (AIH = 20, ASC =22, PSC =13). AIH, ASC and PSC exhibited increasing age at the onset (AIH to PSC, p < 0.01). The area under the receiver operating characteristic curve for gamma-glutamyltranspeptidase (GGT) combined with alkaline phosphatase/aspartate aminotransferase (ALP/AST) ratio in predicting sclerosing cholangitis was 0.94, with a sensitivity of 86 % and a specificity of 94 %. At the last follow-up (median duration 5,8 years, interquartile range [IQR] 2,9–10,2, n = 45), 15 patients (33 %) developed portal hypertension, 2 patients (4 %) underwent liver transplantation, no patient died. A cohort of childhood-onset AILD managed at a single centre reveals a temporal trend in the onset of AIH, ASC and PSC, with progressively older ages. Elevated GGT levels combined with a high ALP/AST ratio predict the diagnosis of sclerosing cholangitis. The occurrence of liver-related adverse events in one-third of patients highlights the progressive nature of paediatric-onset AILD. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

18. Recommendations in pre-procedural imaging assessment for TAVI intervention: SIC-SIRM position paper part 2 (CT and MR angiography, standard medical reporting, future perspectives)

Author

Marano, Riccardo, Pontone, Gianluca, Agricola, Eustachio, Alushi, Brunilda, Bartorelli, Antonio, Cameli, Matteo, Carrabba, Nazario, Esposito, Antonio, Faletti, Riccardo, Francone, Marco, Galea, Nicola, Golino, Paolo, Guglielmo, Marco, Palmisano, Anna, Petronio, Sonia, Petullà, Maria, Pradella, Silvia, Ribichini, Flavio, Romeo, Francesco, Russo, Vincenzo, Scandura, Salvatore, Schicchi, Nicolò, Spaccarotella, Carmen, Tomai, Fabrizio, Indolfi, Ciro, and Centonze, Maurizio

Published
2022
Full Text
View/download PDF

19. Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment

Author

Sen, Sayan, Ahmad, Yousif, Dehbi, Hakim-Moulay, Howard, James P, Iglesias, Juan F, Al-Lamee, Rasha, Petraco, Ricardo, Nijjer, Sukhjinder, Bhindi, Ravinay, Lehman, Sam, Walters, Darren, Sapontis, James, Janssens, Luc, Vrints, Christiaan J, Khashaba, Ahmed, Laine, Mika, Van Belle, Eric, Krackhardt, Florian, Bojara, Waldemar, Going, Olaf, Härle, Tobias, Indolfi, Ciro, Niccoli, Giampaolo, Ribichini, Flavio, Tanaka, Nobuhiro, Yokoi, Hiroyoshi, Takashima, Hiroaki, Kikuta, Yuetsu, Erglis, Andrejs, Vinhas, Hugo, Silva, Pedro Canas, Baptista, Sérgio B, Alghamdi, Ali, Hellig, Farrel, Koo, Bon-Kwon, Nam, Chang-Wook, Shin, Eun-Seok, Doh, Joon-Hyung, Brugaletta, Salvatore, Alegria-Barrero, Eduardo, Meuwissen, Martijin, Piek, Jan J, van Royen, Niels, Sezer, Murat, Di Mario, Carlo, Gerber, Robert T, Malik, Iqbal S, Sharp, Andrew SP, Talwar, Suneel, Tang, Kare, Samady, Habib, Altman, John, Seto, Arnold H, Singh, Jasvindar, Jeremias, Allen, Matsuo, Hitoshi, Kharbanda, Rajesh K, Patel, Manesh R, Serruys, Patrick, Escaned, Javier, and Davies, Justin E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Heart Disease - Coronary Heart Disease, Heart Disease, Clinical Research, Cardiovascular, Good Health and Well Being, Aged, Coronary Angiography, Coronary Stenosis, Coronary Vessels, Female, Fractional Flow Reserve, Myocardial, Humans, Male, Middle Aged, Myocardial Revascularization, coronary stenosis, fractional flow reserve, instantaneous wave-free ratio, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundPhysicians are not always comfortable deferring treatment of a stenosis in the left anterior descending (LAD) artery because of the perception that there is a high risk of major adverse cardiac events (MACE). The authors describe, using the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation) trial, MACE rates when LAD lesions are deferred, guided by physiological assessment using fractional flow reserve (FFR) or the instantaneous wave-free ratio (iFR).ObjectivesThe purpose of this study was to establish the safety of deferring treatment in the LAD using FFR or iFR within the DEFINE-FLAIR trial.MethodsMACE rates at 1 year were compared between groups (iFR and FFR) in patients whose physiological assessment led to LAD lesions being deferred. MACE was defined as a composite of cardiovascular death, myocardial infarction (MI), and unplanned revascularization at 1 year. Patients, and staff performing follow-up, were blinded to whether the decision was made with FFR or iFR. Outcomes were adjusted for age and sex.ResultsA total of 872 patients had lesions deferred in the LAD (421 guided by FFR, 451 guided by iFR). The event rate with iFR was significantly lower than with FFR (2.44% vs. 5.26%; adjusted HR: 0.46; 95% confidence interval [CI]: 0.22 to 0.95; p = 0.04). This was driven by significantly lower unplanned revascularization with iFR and numerically lower MI (unplanned revascularization: 2.22% iFR vs. 4.99% FFR; adjusted HR: 0.44; 95% CI: 0.21 to 0.93; p = 0.03; MI: 0.44% iFR vs. 2.14% FFR; adjusted HR: 0.23; 95% CI: 0.05 to 1.07; p = 0.06).ConclusionsiFR-guided deferral appears to be safe for patients with LAD lesions. Patients in whom iFR-guided deferral was performed had statistically significantly lower event rates than those with FFR-guided deferral.

Published
2019

26. NBAS Variants Are Associated with Quantitative and Qualitative NK and B Cell Deficiency

Author

Lenz, Dominic, Pahl, Jens, Hauck, Fabian, Alameer, Seham, Balasubramanian, Meena, Baric, Ivo, Boy, Nikolas, Church, Joseph A., Crushell, Ellen, Dick, Anke, Distelmaier, Felix, Gujar, Jidnyasa, Indolfi, Giuseppe, Lurz, Eberhard, Peters, Bianca, Schwerd, Tobias, Serranti, Daniele, Kölker, Stefan, Klein, Christoph, Hoffmann, Georg F., Prokisch, Holger, Greil, Johann, Cerwenka, Adelheid, Giese, Thomas, and Staufner, Christian

Published
2021
Full Text
View/download PDF

27. SIRM–SIC appropriateness criteria for the use of Cardiac Computed Tomography. Part 1: Congenital heart diseases, primary prevention, risk assessment before surgery, suspected CAD in symptomatic patients, plaque and epicardial adipose tissue characterization, and functional assessment of stenosis

Author

Esposito, Antonio, Francone, Marco, Andreini, Daniele, Buffa, Vitaliano, Cademartiri, Filippo, Carbone, Iacopo, Clemente, Alberto, Guaricci, Andrea Igoren, Guglielmo, Marco, Indolfi, Ciro, La Grutta, Ludovico, Ligabue, Guido, Liguori, Carlo, Mercuro, Giuseppe, Mushtaq, Saima, Neglia, Danilo, Palmisano, Anna, Sciagrà, Roberto, Seitun, Sara, Vignale, Davide, Pontone, Gianluca, and Carrabba, Nazario

Published
2021
Full Text
View/download PDF

28. Coronary microvascular dysfunction beyond the spectrum of chronic coronary syndromes.

Author

Belmonte, Marta, Foà, Alberto, Paolisso, Pasquale, Bergamaschi, Luca, Gallinoro, Emanuele, Polimeni, Alberto, Scarsini, Roberto, Muscoli, Saverio, Amicone, Sara, De Vita, Antonio, Villano, Angelo, Angeli, Francesco, Armillotta, Matteo, Sucato, Vincenzo, Tremamunno, Saverio, Morrone, Doralisa, Indolfi, Ciro, Filardi, Pasquale Perrone, Ribichini, Flavio, and Lanza, Gaetano Antonio

Abstract

The prevalence of coronary microvascular dysfunction (CMD) beyond the spectrum of chronic coronary syndromes (CCS) is non-negligible, pertaining to pathophysiological and therapeutical implications. Thanks to the availability of accurate and safe non-invasive technique, CMD can be identified as a key player in heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis. While CMD is widely recognized as a cause of myocardial ischemia leading to a worse prognosis even in the absence of obstructive coronary artery disease, the characterization of CMD patterns beyond CCS might provide valuable insights on the underlying disease progression, being potentially a "red flag" of adverse cardiac remodeling and a major determinant of response to therapy and outcomes. In this review, we aimed to provide an overview of the latest evidence on the prevalence, mechanistic and prognostic implications of CMD beyond the spectrum of CCS (i.e. heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis). [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Appropriate use criteria for cardiovascular magnetic resonance imaging (CMR): SIC—SIRM position paper part 1 (ischemic and congenital heart diseases, cardio-oncology, cardiac masses and heart transplant)

Author

Pontone, Gianluca, Di Cesare, Ernesto, Castelletti, Silvia, De Cobelli, Francesco, De Lazzari, Manuel, Esposito, Antonio, Focardi, Marta, Di Renzi, Paolo, Indolfi, Ciro, Lanzillo, Chiara, Lovato, Luigi, Maestrini, Viviana, Mercuro, Giuseppe, Natale, Luigi, Mantini, Cesare, Polizzi, Aldo, Rabbat, Mark, Secchi, Francesco, Secinaro, Aurelio, Aquaro, Giovanni Donato, Barison, Andrea, and Francone, Marco

Published
2021
Full Text
View/download PDF

41. Incidence, Predictors, and Prognostic Impact of Neurologic Events After TAVR According to VARC-3 Criteria.

Author

Avvedimento, Marisa, Cepas-Guillén, Pedro, Garcia, Carla Benavent, Franzone, Anna, Sorrentino, Sabato, Indolfi, Ciro, Esposito, Giovanni, Mohammadi, Siamak, Pelletier-Beaumont, Emilie, and Rodés-Cabau, Josep

Abstract

The Valve Academic Research Consortium (VARC)-3 definition for neurologic events after transcatheter aortic valve replacement (TAVR) lacks clinical validation. This study sought to determine the incidence, predictors, and clinical impact of neurologic events following TAVR as defined by VARC-3 criteria. This was a multicenter study including 2,924 patients with severe aortic stenosis undergoing TAVR. Based on Neurologic Academic Research Consortium (NeuroARC) classification, neurologic events were classified as NeuroARC type 1 (stroke), NeuroARC type 2 (covert central nervous system injury), and NeuroARC type 3 (transient ischemic attack and delirium). Baseline, procedural, and follow-up data were prospectively collected in a dedicated database. After a median follow-up of 13 (7-37) months, neurologic events occurred in 471 patients (16.1%), NeuroARC type 1, 2, and 3 in 37.4%, 4.7%, and 58.0% of cases, respectively, and the majority (58.6%) were periprocedural. Advanced age, chronic kidney disease, atrial fibrillation, major vascular complications, and in-hospital bleeding determined an increased risk of periprocedural events (P < 0.03 for all). Neurologic events occurring during the periprocedural time frame were independently associated with a substantial increase in mortality at 1 year after the intervention (HR: 1.91; 95% CI: 1.23-2.97; P = 0.004). However, although NeuroARC type 1 was associated with an increased mortality risk (IRR: 3.38; 95% CI: 2.30-5.56; P < 0.001 and IRR: 21.7; 95% CI: 9.63-49.1; P < 0.001 for ischemic and hemorrhagic stroke, respectively), the occurrence of NeuroARC type 3 events had no impact on mortality. Neurologic events after TAVR were associated with poorer short- and long-term survival. This correlation was related to the type of NeuroARC event defined by the VARC-3 criteria. Given the negative impact on clinical outcomes, every attempt should be made to reduce the risk of neurologic complications after TAVR. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. FDG PET in response evaluation of bulky masses in paediatric Hodgkin’s lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial

Author

Lopci, Egesta, Mascarin, Maurizio, Piccardo, Arnoldo, Castello, Angelo, Elia, Caterina, Guerra, Luca, Borsatti, Eugenio, Sala, Alessandra, Todesco, Alessandra, Zucchetta, Pietro, Farruggia, Piero, Cistaro, Angelina, Buffardi, Salvatore, Bertolini, Patrizia, Bianchi, Maurizio, Moleti, Maria Luisa, Bunkheila, Feisal, Indolfi, Paolo, Fagioli, Franca, Garaventa, Alberto, Burnelli, Roberta, and AIEOP Hodgkin Lymphoma Study Group, Italy

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results